如何让创新药真正走向患者，成为吴德沛近些年履职的出发点。一方面，他与相关创新药企业开展联合 研究，推动临床研究加速，让更多患者在规范的临床研究中获得治疗机会。"很多创新药还没上市，但 已经在临床研究中展现出效果，对不少患者来说，进入临床研究就是新的希望。创新必须走向临床，最 终回到患者身上。"吴德沛说。 履职仍在继续。在去年的调研基础上，吴德沛今年把关注点进一步转向大数据赋能医疗与精准诊疗，围 绕医疗数据共享、临床研究和精准诊疗能力提升开展调研、建言献策。"医疗正在进入数据驱动的时 代，只有把数据用好，才能让更多患者更早受益。"吴德沛说。（记者白光迪） 记者手记 履职就是要持续跟进 从病房到实验室，再到调研建言的现场，解决急难愁盼问题贯穿吴德沛工作的始终。作为医药卫生界别 全国政协委员，他面对的难题跨越医学、产业与政策多个领域。然而无论是在病房里守护患者的治疗希 望，还是在调研中推动创新药进入多层次医疗保障体系，他始终选择迎难而上、持续推进。对他而言， 没有哪一件事可以轻言放弃——一次次坚持与推进，正是对守护生命最庄重的回应。 另一方面，吴德沛把更多精力投入到调研。去年全国两会前，他围绕创新药可及性展开系统调 ...

Core Viewpoint - The company, Jiukang Biotechnology, has evolved from a代理商 to a leading player in the IVD (in vitro diagnostics) industry in China, focusing on innovation and precision diagnosis to drive future growth [2][3]. Group 1: Company Development - Jiukang Biotechnology started as an代理商 for an international IVD brand and quickly gained recognition, becoming a service supplier for the national quality control products [3]. - The company has maintained a strong client base, with over 70% of top-tier hospitals in China being loyal customers [3]. - The company has significantly increased its R&D investment, with R&D accounting for 21% of sales revenue in the first three quarters of 2025, up from 14% in the same period of 2024 [3]. Group 2: Product Innovation - R&D efforts are focused on new products in areas such as pathology, chemiluminescence, and coagulation, leading to an increase in medical device registrations and patents [4]. - The company has launched new products, including a high-speed fully automated chemiluminescence immunoassay analyzer and a biochemical analyzer, enhancing its competitive edge in the market [4]. - Jiukang's first AI project, a prostate cancer AI interpretation software, has been developed and validated, with plans to expand into smart pathology products [4]. Group 3: Strategic Partnerships - The company aims to become a platform enterprise in the IVD sector, collaborating with leading international firms to leverage their strengths and expand into global markets [5]. - A strategic partnership with Abbott began in 2013, allowing Jiukang to share its patented processes for global product production, resulting in profit-sharing [6]. - In 2020, a significant partnership with China National Pharmaceutical Group (Sinopharm) was established, enhancing sales channels and accelerating growth, with Sinopharm becoming the largest shareholder [6]. Group 4: Industry Trends - The IVD industry in China is rapidly developing, with significant growth potential driven by medical reform and innovation [7]. - The industry is expected to undergo a transformation towards high-quality upgrades, with a focus on value competition rather than price competition [7]. - Emerging technologies such as molecular diagnostics and AI-assisted diagnostics are anticipated to become core competitive advantages, with an emphasis on domestic alternatives in high-end markets [7].

Group 1 - The first clinical application guidelines for the use of Gilteritinib in adults with FLT3-mutated acute myeloid leukemia (AML) have been officially released, aiming to provide authoritative clinical guidance for standardized diagnosis and treatment [1][2] - The guidelines were developed by the Chinese Society of Clinical Oncology (CSCO) Leukemia Expert Committee, integrating global evidence and Chinese clinical practices, covering key areas such as FLT3 mutation testing, Gilteritinib treatment regimens, minimal residual disease (MRD) monitoring, and adverse reaction management [1][2] - The guidelines emphasize the importance of high-sensitivity MRD dynamic monitoring as a core method for guiding post-transplant maintenance therapy and individualized interventions, marking a shift towards precision medicine in the treatment of FLT3-mutated AML [2] Group 2 - Gilteritinib, a second-generation type I FLT3 inhibitor, has been approved in China for the treatment of relapsed or refractory FLT3-mutated AML since 2021, and has accumulated substantial evidence in new diagnosis and post-transplant maintenance therapy [2] - The release of these guidelines is expected to enhance the long-term survival rates of patients through standardized testing and precise medication, contributing to the high-quality development of the blood cancer prevention and treatment system in China [2]

Core Insights - The "People's Good Doctor Jinshan Camellia Plan" conference highlighted advancements in cancer prevention and control, focusing on high-quality development in the field [1] Group 1: Cancer Treatment Advances - Hepatobiliary tumor treatment has entered an immune-dominant phase, significantly extending patient survival and creating curative opportunities for inoperable tumors [1] - Lung cancer patients have seen improved survival rates due to the promotion of precision diagnosis and treatment, with breakthroughs in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) [2] - Innovative drugs and treatment strategies in esophageal and gastric cancers have led to significant clinical advancements, although challenges in standardization and precision screening remain [2] Group 2: Multidisciplinary Collaboration - A multidisciplinary collaboration model is becoming mainstream in cancer treatment, allowing for personalized treatment plans through joint consultations among various specialists [4] - There is a need for improved management of patient follow-ups and a more balanced regional development in cancer prevention and treatment [4] Group 3: Emerging Treatment Modalities - Immunotherapy combined with chemotherapy has become a first-line treatment for advanced nasopharyngeal carcinoma, with ongoing exploration of different intervention models [3] - The application of CAR-T cell therapy and targeted drugs has provided long-term survival opportunities for previously hard-to-treat hematological cancer patients [3] Group 4: Future Directions - Continuous innovation in clinical research and acceleration of new treatment technologies are essential for enhancing cancer prevention and treatment systems [5] - The focus should be on early screening, diagnosis, and treatment management to provide patients with better survival prospects [5]

Core Insights - Cancer remains a significant threat to public health and hinders the improvement of residents' health levels [1] - The "People's Good Doctor · Jinshan Camellia Plan" aims to promote high-quality cancer prevention and control through clinical research and innovation [3] Group 1: Cancer Treatment Advances - Current cancer treatment has entered a new era characterized by precision, individualization, and multidisciplinary collaboration [3] - Immunotherapy, in conjunction with targeted and interventional therapies, has significantly extended patient survival rates and created curative opportunities for some inoperable tumors [1] - The promotion of precision diagnosis and treatment, along with the application of targeted and immunotherapy, has effectively improved the survival and quality of life for lung cancer patients [1] Group 2: Future Directions in Cancer Care - Future cancer treatment should focus on precise stratification, mechanism collaboration, and comprehensive management throughout the disease course [1] - There is a need to enhance early screening and diagnosis for high-risk populations, optimize combined treatment plans, and encourage young doctors to engage in clinical research and innovation [1] - The cancer prevention and treatment system should be improved to achieve comprehensive management of early screening, diagnosis, and treatment, providing patients with greater hope for survival [3]

Product Registration - The company has received medical device registration certificates for four products from the National Medical Products Administration [1] - Two of the approved respiratory "small joint inspection" products offer high sensitivity, specificity, and ease of operation, providing reports in as fast as 30 minutes [1] - The "small joint inspection" series has now expanded to 10 products, enhancing the company's "6/3+X respiratory infection nucleic acid rapid detection" system [1] Clinical Impact - The approved respiratory products are crucial for early identification of pathogens in respiratory infections, which is vital for precise medication and reducing antibiotic resistance [1] - The EB virus nucleic acid detection kit has undergone significant technical upgrades, improving detection sensitivity and supporting various specimen types [2] - The CYP3A5 gene polymorphism nucleic acid detection kit is the ninth product in the company's drug genome series, aimed at optimizing clinical medication plans for transplant patients [2]

Core Viewpoint - The conference aims to enhance the diagnosis and treatment of gastrointestinal diseases in the region, aligning with the "Healthy China" strategy and focusing on gastric cancer prevention [1][3] Group 1: Conference Overview - The conference, hosted by the Tengzhou Central People's Hospital, included the "2025 Good City" Gastroenterology Forum and the Zaozhuang Medical Association Gastroenterology Annual Meeting [1] - Key figures such as Zhu Guangyao, the hospital's party secretary, and Li Shuhui, chairman of the Zaozhuang Medical Association Gastroenterology Committee, participated in the event [1][3] Group 2: Expert Contributions - Professor Wang Yongjun from Capital Medical University shared insights on the development trends and clinical practices in gastroenterology, emphasizing the importance of standardized treatment [3] - Renowned experts from various institutions discussed four core topics, providing in-depth academic exchanges [3][5] Group 3: Key Topics Discussed - In the field of endoscopic treatment for biliary and pancreatic diseases, experts detailed ERCP standardized operation techniques and advancements in biliary and pancreatic endoscopy [5] - The focus on early diagnosis and treatment of gastrointestinal tumors included discussions on endoscopic diagnosis and strategies for colorectal cancer screening [5][6] - The importance of multidisciplinary collaboration (MDT) in treating severe cases of acute pancreatitis was highlighted, along with personalized treatment plans based on the latest clinical guidelines [5][6] - The significance of standardized detection methods and eradication treatment for Helicobacter pylori in gastric cancer prevention was thoroughly analyzed [6] Group 4: Conference Impact - The conference served as a platform for efficient academic exchange and skill enhancement in the field of gastroenterology for Tengzhou and surrounding areas [6] - Participants gained insights into the latest diagnostic pathways for key gastrointestinal diseases, which will guide future clinical work and improve treatment quality [6]

Core Insights - The National Medical Products Administration (NMPA) has approved two innovative medical devices: the AI-Rad Companion™ Prostate MR software by Siemens Medical and the G-Branch™ thoracoabdominal aortic stent system by Xianjian Technology, marking a significant advancement in China's medical device industry from "catching up" to "leading" [2][19][27]. Group 1: G-Branch™ Thoracoabdominal Aortic Stent System - The G-Branch™ system is designed for complex vascular conditions, specifically targeting thoracoabdominal aortic aneurysms (TAAA) and thoracoabdominal aortic dissections (TADA), providing a minimally invasive repair solution [7][8]. - This system includes five components: main stent, peripheral stent, extension stent, bifurcated main stent, and iliac extension stent, ensuring safety and effectiveness during surgery [7][12]. - The G-Branch™ system features a unique "dual inner and dual outer" hybrid branch design, which mimics the natural taper of the thoracoabdominal aorta, significantly reducing risks associated with traditional systems [8][9]. - Clinical studies demonstrated a 99.7% success rate in branch reconstruction and a 98.6% overall survival rate, indicating the system's reliability in real-world applications [13]. Group 2: AI-Rad Companion™ Prostate MR Software - The AI-Rad Companion™ Prostate MR software is a localized version of Siemens' global AI-Rad Companion family, designed to assist in the analysis of multiparametric MRI for suspected prostate cancer in men aged 40 and above [19][20]. - This software aims to improve diagnostic accuracy and reduce unnecessary biopsies, with a negative predictive value exceeding 95%, potentially avoiding 20-30% of negative biopsies [20][24]. - The software consists of two main modules: a confirmation module for image loading and patient verification, and a settings module that integrates deep learning for prostate configuration and lesion detection [23]. - Clinical trials showed a sensitivity of 92% and specificity of 88%, with the software enhancing cancer detection rates by 18% and reducing report generation time significantly [24][25]. Group 3: Company Profiles - Xianjian Technology, founded in 2003, is a leading Chinese company in cardiovascular and peripheral vascular intervention medical devices, with a market capitalization exceeding 10 billion HKD [14][16]. - Siemens Medical, a subsidiary of Siemens Healthineers, has been operating in China for over 20 years and plans to launch 20 "China-made" products in 2025, reinforcing its commitment to local innovation [27].

Core Viewpoint - The article highlights the approval and significance of the uCT Ultima, China's first photon-counting spectral CT developed by United Imaging Healthcare, marking a major advancement in medical imaging technology [5][6]. Group 1: Product Development - The uCT Ultima has received approval from the National Medical Products Administration, representing a significant milestone in the commercialization of photon-counting spectral CT technology in China [5]. - This technology is considered a "crown jewel" in medical devices and is referred to as the "third technological revolution" in CT imaging [5]. Group 2: Technological Advantages - The uCT Ultima features a semiconductor detector that provides higher spatial resolution imaging, direct multi-energy spectrum imaging, and lower radiation dose imaging, significantly enhancing precision diagnosis [6]. - The pixel area of the detector has been reduced to one-ninth of its original size, allowing for the visualization of finer pathological structures and achieving ultra-high resolution imaging with full collimation coverage [6]. - Radiation dose reduction can reach 60% to 70%, and in certain organs, it can be reduced by 80% to 90%, making CT scans safer for patients [6]. Group 3: Market Position - United Imaging Healthcare is now the third company globally and the first in China to successfully commercialize photon-counting CT technology [6]. - The uCT Ultima has already been implemented in clinical research at Fudan University Zhongshan Hospital and Shanghai Jiao Tong University School of Medicine Ruijin Hospital [6].

Core Insights - The increasing societal focus on blood health and support for acute myeloid leukemia (AML) patients is highlighted, with a call for public education on prevention, diagnosis, treatment, and recovery [1][2] - The treatment of AML is evolving towards precision and diversification, with targeted therapies marking the entry into a "precision era" [1] - The application of second-generation FLT3 inhibitors is significantly improving the prognosis for patients with FLT3 mutations, extending median overall survival to 9.3 months while reducing side effects [1] - The widespread use of minimal residual disease (MRD) monitoring technology is aiding in the precise detection of residual cancer cells, allowing for timely treatment adjustments and reduced relapse risk [1] Treatment Recommendations - It is advised that families with a leukemia diagnosis engage actively with healthcare providers to choose appropriate medical institutions based on economic conditions, accessibility, resource allocation, and treatment expectations [2] - The collaboration between the medical community, society, and AML patients' families is expected to enhance the comprehensive management system for AML, making "precision diagnosis and warm recovery" more accessible to families [2]